Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics
The cost-effectiveness of anti-diabetic medications has deteriorated substantially over time, particularly in OECD countries, despite stable therapeutic benefits. These findings highlight the need for dynamic approaches to cost-effectiveness thresholds and robust price negotiations to ensure sustainable access to innovative therapies.
Authors
- Huiqiao Gu (ORCID: https://orcid.org/0009-0005-6250-4137)
- Yawen Jiang (ORCID: https://orcid.org/0000-0002-0498-0662)
- Xinyu Zhao (ORCID: https://orcid.org/0009-0005-6252-7259)
- Bingxin Hu (ORCID: https://orcid.org/0000-0002-5208-5195)
- Wenjie Hu (ORCID: https://orcid.org/0000-0001-8117-3381)
- Yu Cui (ORCID: https://orcid.org/0000-0002-7799-810X)
Institutions
- Sun Yat-sen University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1080/14737167.2025.2451747
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Basic and Applied Basic Research Foundation of Guangdong Province